Newsletter | September 9, 2026

09.09.26 -- Where AI Risk Meets Patient Trust In Today's Clinical Trials

SPONSOR

 

 

Join this Clinical Leader Live on 9-22-26 to explore smarter ways to evaluate site capabilities, patient availability, recruitment potential, protocol burden, and virtual versus in-person trial activities. Discover how sponsors can move beyond feasibility paperwork to make better decisions about whether, where, and how a clinical trial can succeed. Register today to join the discussion.

DECENTRALIZED TRIALS

 

AI Amplifies Capabilities But Also Risks: Learn The Legal Consequences Of AI In Clinical Research

Guest Column | By Brittnie Panetta, Matthews & Associates

Companies that successfully use AI are those that understand technology magnifies accountability. Anyone that fails to internalize that lesson could find themselves defending the very systems they relied on to bring those products to market.

 

Patient Trust And Engagement In The Age Of Decentralized Trials

Article | By Mike Stratton, CSS

To truly maximize enrollment in decentralized models, sponsors must invest in human connection to build the trust needed to move patients from awareness to active participation.

 

TrialKit Engage For Televisits

Product | Crucial Data Solutions

Conduct secure video based visits, manage study schedules, and keep participants connected through a single unified platform.

TRIAL MANAGEMENT

 

Expanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients

Guest Column | A conversation among Robert E. Hoffman, CytoDyn, Jay Lalezari, MD, and Clinical Leader Executive Editor Abby Proch

CEO Jay Lalezari and CFO Robert E. Hoffman share how CytoDyn meet patient needs when they approach trial design for cancer trials.

 

Improving Clinical Trial Label Translation Through Centralized Reuse And Control

Case Study | Thermo Fisher Scientific

Eliminate workflow inefficiencies and regulatory risk in global trials with a centralized translation framework and validated phrase library for consistent, cost-effective execution.

 

The Impact Of GLP-1s On Cardiovascular Clinical Development

Webinar | PPD Clinical Research Business of Thermo Fisher Scientific

As GLP-1 use expands, cardiovascular research is evolving. Discover key trial design considerations, development trends, and insights driving cardiometabolic innovation.

 

Human Abuse Potential: Selecting A Positive Control

Video | Dr. Vince Clinical Research

Choosing an effective positive control in HAP studies is critical but not always straightforward. Learn how to justify comparator and dose selection.

 

Clinical Trial Services For Phase 1-3 Studies

Product | 20/20 Onsite

Mobile ophthalmic clinical research and clinical trial on-site support services designed to address challenges across all trial phases and ensure reliable protection of ocular endpoints.
Connect With Clinical Leader: